Gene: MYO10

4651
-
myosin X
protein-coding
5p15.1
Ensembl:ENSG00000145555 MIM:601481 Vega:OTTHUMG00000161822 UniprotKB:Q9HD67
NC_000005.10
SNP Mapped
3   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.031e-1 (AD)  6.755e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs29452chr5:16910496 (GRCh38.p7)C>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs10063505chr5:16822062 (GRCh38.p7)C>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs12188582chr5:16818254 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
APCDD10.889
SASH10.883
PPARA0.881
BMP70.874
GOLIM40.873
HEPACAM0.869
SOX210.862
AMOT0.86
ADD30.858
KCNJ100.855

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MCHR1-0.458
CACNA1F-0.448
ANKRD34C-0.445
OSBPL10-0.444
HTR7-0.433
NRG1-0.428
FHL2-0.427
PAQR9-0.425
SUSD1-0.424
RNF128-0.423

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of MYO10 mRNA19933214
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of MYO10 mRNA"21346803
C0144643,4-dichloroaniline"3,4-dichloroaniline results in increased expression of MYO10 mRNA"24172598
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of MYO10 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C0207389,10-dihydro-9,10-dihydroxybenzo(a)pyrene"9,10-dihydro-9,10-dihydroxybenzo(a)pyrene results in decreased expression of MYO10 mRNA"26238291
D000082AcetaminophenAcetaminophen affects the expression of MYO10 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of MYO10 mRNA21641981
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MYO10 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of MYO10 mRNA22100608
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of MYO10 mRNA24449571
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MYO10 mRNA22316170|2623829
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MYO10 mRNA19770486|2156981
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MYO10 mRNA"19150397|2038263
D004958EstradiolEstradiol affects the expression of MYO10 mRNA14699072
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of MYO10 mRNA19619570
D004958EstradiolEstradiol results in increased expression of MYO10 mRNA19619570
D004958EstradiolEstradiol results in decreased expression of MYO10 mRNA20068009
C006780bisphenol Abisphenol A results in decreased expression of MYO10 mRNA20678512
C006780bisphenol Abisphenol A results in increased expression of MYO10 mRNA21932408|2606340
C006780bisphenol Abisphenol A results in decreased expression of MYO10 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of MYO10 gene28505145
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in increased expression of MYO10 mRNA15336504
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of MYO10 mRNA17484886
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
D002737ChloropreneChloroprene results in decreased expression of MYO10 mRNA23125180
D002737ChloropreneChloroprene results in increased expression of MYO10 mRNA23125180
C018021cobaltous chloridecobaltous chloride results in decreased expression of MYO10 mRNA19320972
D019327Copper SulfateCopper Sulfate affects the expression of MYO10 mRNA19549813
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of MYO10 mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of MYO10 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of MYO10 mRNA27392435
D004041Dietary Fats[Dietary Fats co-treated with resveratrol] results in decreased expression of MYO10 mRNA21852083
D011397Promegestonemethoxyacetic acid promotes the reaction [Promegestone results in increased expression of MYO10 mRNA]15103026
D011397PromegestonePromegestone results in increased expression of MYO10 mRNA15103026
C024629dimethyl phthalatedimethyl phthalate affects the expression of MYO10 mRNA26924002
D004237DiuronDiuron metabolite results in increased expression of MYO10 mRNA24172598
D004317DoxorubicinDoxorubicin affects the methylation of MYO10 gene28962528
C118739entinostatentinostat results in increased expression of MYO10 mRNA27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO10 mRNA22079256
D005492Folic AcidFolic Acid affects the expression of MYO10 mRNA17320366
C069837fullerene C60fullerene C60 results in decreased expression of MYO10 mRNA19167457
D007213IndomethacinIndomethacin results in decreased expression of MYO10 mRNA28201806
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of MYO10 mRNA27392435
D048628KetolidesKetolides analog results in increased expression of MYO10 mRNA24967691
C045463leflunomideleflunomide results in increased expression of MYO10 mRNA28988120
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of MYO10 mRNA"24972896
C042720mercuric bromidemercuric bromide results in increased expression of MYO10 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C013598methoxyacetic acidmethoxyacetic acid promotes the reaction [Promegestone results in increased expression of MYO10 mRNA]15103026
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of MYO10 mRNA28001369
D008767Methylmercury CompoundsMethylmercury Compounds affects the expression of MYO10 mRNA21664453
D008767Methylmercury CompoundsMethylmercury Compounds affects the expression of MYO10 mRNA21664453
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of MYO10 mRNA26011545
C008493methylselenic acidmethylselenic acid results in decreased expression of MYO10 mRNA18548127
D016685MitomycinMYO10 protein affects the susceptibility to Mitomycin16217747
C029938nickel sulfatenickel sulfate results in increased expression of MYO10 mRNA22714537
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of MYO10 mRNA26272509
C006253pirinixic acidpirinixic acid results in decreased expression of MYO10 mRNA17426115
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO10 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of MYO10 mRNA22079256
C513428pyrachlostrobinpyrachlostrobin results in increased expression of MYO10 mRNA27029645
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride affects the expression of MYO10 mRNA14699072
C059514resveratrol[Dietary Fats co-treated with resveratrol] results in decreased expression of MYO10 mRNA21852083
C010327salinomycinsalinomycin results in decreased expression of MYO10 mRNA19682730
D012822Silicon DioxideSilicon Dioxide results in increased expression of MYO10 mRNA19073995
C017947sodium arsenitesodium arsenite affects the methylation of MYO10 gene28589171
C017947sodium arsenitesodium arsenite results in increased expression of MYO10 mRNA22714537
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of MYO10 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of MYO10 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MYO10 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MYO10 mRNA16120747|1993321
D014212TretinoinTretinoin results in decreased expression of MYO10 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of MYO10 mRNA24935251
C012589trichostatin Atrichostatin A results in increased expression of MYO10 mRNA24935251|2627250
C057693troglitazonetroglitazone results in increased expression of MYO10 mRNA19140230
C057693troglitazonetroglitazone results in decreased expression of MYO10 mRNA28973697
D014520UrethaneUrethane results in decreased expression of MYO10 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO10 mRNA"27188386
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MYO10 mRNA25979313|2627250
D014635Valproic AcidValproic Acid results in increased expression of MYO10 mRNA19101580|2317975
D014638VanadatesVanadates results in increased expression of MYO10 mRNA22714537
D001335Vehicle EmissionsVehicle Emissions affects the methylation of MYO10 gene25560391
D024483Vitamin K 3Vitamin K 3 affects the expression of MYO10 mRNA20044591
C111237vorinostatvorinostat results in decreased expression of MYO10 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003774motor activity-EXP12055636  
GO:0003777microtubule motor activity-IEA-  
GO:0005515protein binding-IPI18570893  21321230  21642953  25416956  
GO:0005516calmodulin binding-IEA-  
GO:0005524ATP binding-IEA-  
GO:0005547phosphatidylinositol-3,4,5-trisphosphate binding-ISS-  
GO:0008017microtubule binding-IEA-  
GO:0030507spectrin binding-IDA23704327  
GO:0030898actin-dependent ATPase activity-ISS-  
GO:0051015actin filament binding-ISS-  
GO:0060002plus-end directed microfilament motor activity-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007018microtubule-based movement-IEA-  
GO:0008360regulation of cell shape-IMP16894163  
GO:0022409positive regulation of cell-cell adhesion-IEA-  
GO:0030705cytoskeleton-dependent intracellular transport-ISS-  
GO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis-TAS-  
GO:0051489regulation of filopodium assembly-IMP16894163  
GO ID GO Term Qualifier Evidence PubMed
GO:0001726ruffle-IEA-  
GO:0005730nucleolus-IDA-  
GO:0005829cytosol-IDA-  
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-IDA-  
GO:0005938cell cortex-IEA-  
GO:0016459myosin complex-IEA-  
GO:0030027lamellipodium-IEA-  
GO:0031527filopodium membrane-IEA-  
GO:0032433filopodium tip-ISS-  
GO:0043005neuron projection-IEA-  
GO:0043025neuronal cell body-IEA-  
KEGG ID KEGG Term
hsa04666Fc gamma R-mediated phagocytosis
Reactome ID Reactome Term Evidence
R-HSA-1266738Developmental BiologyIEA
R-HSA-168249Innate Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisTAS
R-HSA-2029482Regulation of actin dynamics for phagocytic cup formationTAS
R-HSA-373752Netrin-1 signalingIEA
R-HSA-422475Axon guidanceIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal